Dose Escalation Trial in Patients with Solid Tumors
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that the company completed enrollment in the first cohort for its Phase 1 dose escalation clinical trial of JTX-4014 as monotherapy in patients with solid tumors. JTX-4014 is a fully human IgG4 monoclonal antibody designed to specifically bind to PD-1 and block its interaction with its ligands, PD-L1 and PD-L2, to augment anti-tumor T cell activity. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates.
“We believe combination therapy will be the mainstay of cancer immunotherapy treatment and that PD-1 checkpoint inhibitors like JTX-4014 will be an important component of future regimens,” said Elizabeth Trehu, M.D., chief medical officer of Jounce Therapeutics. “As we continue to build and progress our immunotherapy pipeline, including macrophage and other cold tumor target treatments, we believe it is important for us to have our own PD-1 inhibitor to potentially combine with these novel agents.”
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics and to identify the recommended Phase 2 dose of JTX-4014 monotherapy in patients with advanced solid tumors. For more information on this trial, please visit https://clinicaltrials.gov (Identifier: NCT03790488).
JTX-4014 is a well-characterized fully human IgG4 monoclonal antibody designed to block binding to PD-L1 and PD-L2. Jounce is developing JTX-4014 for potential use in combination with its pipeline of future product candidates. JTX-4014 is currently in Phase 1 clinical development.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment (TME) to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce has three development stage programs: its two clinical product candidates, JTX-2011, a monoclonal antibody that binds to and activates ICOS, and JTX-4014, a monoclonal antibody that binds to PD-1 to be used in combination with its pipeline of future product candidates, and JTX-8064, a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2 (LILRB2) that is currently in the IND-enabling phase. For more information, please visit www.jouncetx.com.
Jounce Therapeutics, Inc.
The Yates Network
Source: Jounce Therapeutics, Inc.